Greece vs New Zealand: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Greece
89.0%
in 2025
New Zealand
89.0%
in 2025
Greece rank
72nd
New Zealand rank
72nd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Greece
- New Zealand
How they compare
Greece currently reports 89.0% against 89.0% in New Zealand, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was New Zealand ahead.
Greece ranks 72nd and New Zealand ranks 72nd of 194 countries.
Across the 3 decades both report, Greece averaged higher in 1 and New Zealand in 2.
Head to head by decade
| Decade | Greece | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 43.5% | 43.5% | New Zealand |
| 2010s | 64.0% | 92.6% | 28.6% | New Zealand |
| 2020s | 92.3% | 82.5% | 9.8% | Greece |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Greece or New Zealand?
- Greece, at 89.0% against 89.0% in New Zealand as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Greece and New Zealand?
- 0.0%, with Greece ahead.
- How many years of comparable data are there for Greece and New Zealand?
- 18 years are reported by both, from 2008 to 2025.
- How do Greece and New Zealand rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Greece ranks 72nd and New Zealand ranks 72nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.